iOnctura - a company developing a pipeline of selected assets with novel biology that target and modulate mechanisms that drive immunosuppression in the tumour microenvironment (TME) to boost efficacy and maximize the therapeutic potential of checkpoint inhibitors - has formed an international Scientific Advisory Board (SAB). The SAB includes some of the world’s leading experts in tumor immunology and checkpoint inhibitor therapy:

  • Dr Sergio A. Quezada, Head of Immune Regulation and Tumour Immunotherapy Research Group at University College London
  • Dr James Larkin, Consultant Medical Oncologist at The Royal Marsden, Vice Chair of the Cancer Research UK Clinical Research Committee and Lead of the Uncommon Cancers Theme at The Royal Marsden/The Institute of Cancer Research NIHR Biomedical Research Centre
  • Professor Stuart Farrow, Director of Biology, Cancer Research UK’s Therapeutic Discovery Laboratories.
  • Dr Joern-Peter Halle, Head of External Innovation & Translational Innovation Platform Immuno-Oncology at the biopharma business of Merck KGaA, Darmstadt, Germany